How the fusion products regulate prostate cancer remains unclear, although it has been observed that an increased incidence of the TMPRSS2:ERG fusion protein in prostate epithelial cells correlates with increased cell invasiveness, poor prognosis and higher rates of malignancy [101]. This evidence concerns the gene TMPRSS2 and Familial prostate cancer.